Abstract library

16 results for "poorly-differentiated".
#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report
Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Medical Doctor Pietro Maria Lombardi
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2939 Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?
Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Z, Zhang T, ...
#3028 Pancreatic Neuroendocrine Neoplasms: Dissecting the Molecular Heterogeneity
Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are a group of rare but biologically and clinically heterogeneous neoplasms with variable patient outcomes. Little is known about the molecular differences between PNENs and the biologic significance of such divergence.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Chi-Fu Kevin Yang
Authors: Yang K C, Kalloger S, Aird J, Lee M, ...
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System
Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Clinical cases/reports
Presenting Author: MD Tomohiro Yamaguchi
#633 Clinical and Prognostic Features of Neuroendocrine Tumor of Unknown Primary Site
Introduction: Neuroendocrine tumors of unknown primary site (NET UPS) are rare and heterogenous tumors with poor prognosis. There is little information available on the treatment and prognosis.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: M.D., Ph.D. Hyun-Jeong Shim
Authors: Shim H J, Kim D, Hwang J E, Lee K H, ...
#808 Characteristics and Determinants of Long-Term Outcome for Resectable Sporadic Non-Functional Pancreatic Neuroendocrine Tumors (NF-PNETs): Updated 16-year Experience from Two Large Chinese Centers
Introduction: Non-functional pancreatic neuroendocrine tumors (NF-PNETs) are increasingly recognized with unique biology.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: M.D. Xu Han
Authors: Jin G, Han X, Jin D, Hu X, ...
Keywords: NF-PNETs
#902 Chemotherapy for Advanced Neuroendocrine Tumors (NETs): Patient Selection Should be Independent of Primary Tumor Site
Introduction: Chemotherapy (CT) is used to treat patients (pts) with advanced poorly-differentiated (Pd); or well-differentiated (Wd) NETs with high-tumor burden (usually of pancreatic (pNET) origin).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Angela Lamarca
#1070 Subtype Classification and Clinicopathological Characteristics of 78 Cases with Gastric Neuroendocrine Neoplasms
Introduction: Gastric NENs are a group of neoplasms with diverse clinicopathological features.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang C, Tan H Y, Liu J X, Luo J, ...